Aurillac, France, May 29th, 2023
Biose Industrie, a contract development manufacturing organisation (CDMO) and a world-leader of live biotherapeutic product (LBP) process development and production, and SBT instruments, a bacteria-focused state-of-the-art industrial equipment supplier, announced a collaboration to implement rapid viable cell counts within Biose’s manufacturing process.
The emerging field of live biotherapeutics faces a number of challenges, especially related to the enumeration of microorganisms. Enumeration of microorganisms is conducted by live biotherapeutic manufacturers to analyze the bacterial composition of their product, throughout the manufacturing journey, for safety and quality purposes.
Traditional approaches to enumerating live biotherapeutic products, such as plate counting and MPN, often pose difficulty and are invariably time-consuming. Through leveraging impedance flow cytometry SBT instruments have developed technologies that greatly reduce the time and difficulty posed by such techniques, allowing for rapid viable cell counts.
In implementing SBT’s technologies within Biose’s manufacturing process, Biose and SBT will create a new industrial standard for enumeration of microorganisms. The implementation of rapid viable cell counts in both process and release testing aims to shorten the journey from clinical trials to market authorization for Biose’s innovative live biotherapeutic companies.
“This collaboration will further solidify Biose’s position as the world leading CDMO within the LBP space”
said Adrien Nivoliez, CEO of Biose Industrie.
“We are proud to lead the field in adopting new technologies to overcome key challenges of LBP manufacturing.”
“SBT instruments is committed to revolutionising the bacterial-enumeration paradigm”
Gustav Skands, CEO of SBT instruments, added.
“Live biotherapeutics present an opportunity to transform the lives of millions of patients, and the faster new medicines get to market, the more patients can be helped. I look forward to seeing this collaboration accelerate the journey of LBPs into the clinic.”
About Biose Industrie
Established in 1951 as a pioneer of industrial fermentation &freeze drying of living bacteria, Biose Industrie pursued its historical development as a cGMP pharmaceutical company dedicated to the manufacturing of microorganisms for drug substance and drug product. In 2017, Biose Industrie started a CDMO/CMO activity, specialized in process & analytical development and industrial manufacturing of microorganisms compliant with pharmaceutical standards and regulations for human health. Today Biose Industrie’s turnover is largely generated by international sales, over half of which are in the USA. Locally, Biose Industrie is at the forefront of the LBPs industrial scene and employs over 350 people and supported by L-GAM and BPI Finance with 80M€ of new CAPEX investments.
About SBT Instruments
SBT Instruments is a pioneering company that develops and produces state-of-the-art products for fast enumeration of microorganisms to support the rapidly growing industry of biotech and biopharma. The core detection principle employed by SBT Instruments is an electrically based flow cytometry technology, referred to as impedance flow cytometry. The technology can detect and enumerate bacteria on a single cell-basis without the use of any labels, stains, or dyes. SBT Instruments has implemented impedance flow cytometry in their flagship product, BactoBox.
